Columbia University

Technology Ventures

CTV Executive Advisors Network

The CTV Executive Advisors Network (XAN) is a new initiative designed to provide mentorship, networking, and marketing and investing advice to promising CTV startups, entrepreneurs and inventors. CTV’s XANs come from backgrounds in entrepreneurship, venture capital, R&D, product design and business development, representing companies including Merck, Alcatel Lucent, Viacom, Amazon, Vimeo, Acorda Therapeutics, Medica Ventures, Shutterstock, IBM, Intel, Sanofi, Xerox, and Google.

Diego Carranza

Area of expertise: 
Biomedical
Forest Laboratories, Roche/Genentech
Year Served: 
Bio 

Diego is a global healthcare executive with 15+ years of progressive experience in the pharma/biotech industry. He has a diverse U.S. and international expertise in business development, commercial strategy & operations and marketing/sales execution. Diego has held positions of increasing responsibility at Roche/Genentech from 1999 to 2011 and Forest Laboratories from 2011- 2014. During his career, he has spearheaded numerous business development opportunities in a variety of deal structures including licensing/M&A/opt-ins that resulted in successful partnerships. Additionally, Diego has developed commercial strategies and coordinated operations for both for pharmaceutical & consumer health businesses, led both commercial & business development teams in a variety of disease areas/markets, integrated operations post-merger as well as directed restructurings globally. Diego holds a BA from University of Buenos Aires and a Master of Science in Industrial Administration (MBA) from Carnegie Mellon University – Tepper School of Business.

Bruce Conway

Area of expertise: 
Biomedical
CPG Consulting, Pars Pharmaceutical Consulting, Johnson & Johnson Pharmaceutical Research & Development
Year Served: 
Bio 

Bruce is the founder and CEO of CPG Consulting where he provides advisory services to Universities and emerging biotech/pharmaceutical companies. He serves as an independent consultant for Pars Pharmaceutical Consulting and as a Senior Advisor to several start-up companies. Bruce has over 18 years of R&D experience progressing projects from early discovery through the clinic. He has held positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research and Development (1996-2006) and The Institutes for Pharmaceutical Discovery (2006-2012). At J&J, Bruce presided over numerous high-profile projects including a novel program which led to an approved therapeutic for type 2 diabetes (Invokana™). Bruce has successfully executed and managed across diverse scientific functions (in vitro biology, in vivo pharmacology and ADME/DMPK) and he possesses a deep understanding of the Drug Discovery and Early Development processes. He also has significant expertise in the identification, evaluation and vetting of novel targets and technologies for incorporation into the R&D portfolio. He has served on cross-functional compound development- and life-cycle management teams in early development and has worked closely with academic scientists and key opinion leaders to assess start-up opportunities. Bruce holds a B.S. in Toxicology from the University of the Sciences in Philadelphia and a Ph.D. in Pharmacology from the Medical College of Virginia. He received postdoctoral training at the University of Massachusetts Medical Center. More detailed information can be found here.

 
 

 

Rick D’Augustine

Area of expertise: 
Biomedical
Cincytech, UMD Inc, Senmed Medical Ventures
Year Served: 
Bio 

Rick has over three decades of medical-industry experience in general management, venture capital investing and technology and business development in both public and private companies. He served as an Executive-in-Residence at Cincytech for almost four years through the end of 2011. Immediately prior to that, he served as president, CEO and a director of UMD Inc., a venture-backed drug-delivery company focusing on women’s health issues. Before joining UMD as its first employee, he spent five years as a group director at Senmed Medical Ventures, a private medical venture capital and business development firm. Rick spent 16 years with Johnson & Johnson and was a founding board member of Cincinnati-based Ethicon Endo-Surgery, initially serving as vice president of administration and CFO, and subsequently as vice president of business development. He was a founding board member of Enable Medical Corp., a private, high-technology medical device company, as well as Atricure Inc., an Enable spinoff focused on surgical treatment of atrial fibrillation, which is now a public company. He also serves or has served as a director on several company boards, including (locally)- Blue Ash Therapeutics, SpineForm, Ischemia Care and Enable Injections. He has a bachelor’s of science degree in mechanical engineering from Rensselaer Polytechnic Institute and an MBA in finance from Seton Hall University. More detailed information can be found here

 

Richard Foster

Area of expertise: 
Biomedical
McKinsey & Company, Lux Capital
Year Served: 
Bio 

Mr. Foster was a Director and Senior Partner with McKinsey & Company where he was responsible for serving clients in the U.S., Europe and Asia focusing on industry sectors including chemicals, electronics, healthcare, retail and consumer goods industries.

During his 31-year tenure with McKinsey & Company and beginning in 1973, Mr. Foster was elected principal (1977) and later Senior Partner and Director (1982), a position he maintained for 22 years. Before leaving McKinsey & Company, Mr. Foster served as founder and Managing Director of McKinsey’s private equity practice. He also founded and led McKinsey’s technology and healthcare sectors. In addition, Mr. Foster led the multi-decade consulting activities with one of McKinsey’s largest clients, a healthcare company.

In April 2011, Mr. Foster joined Lux Capital as a Venture Partner, providing expertise in life sciences and healthcare IT investment.

Mr. Foster currently serves as Chairman of the Board for Ancera Diagnostics and General Semantics, and is on the Board of Directors for Memorial Sloan Ketting Cancer Center, Advantia Health, LeanTaas Analytics, ZocDoc, DrFirst, and SQream Computers.

Mr. Foster received his B.S., M.S. and PhD in Engineering and Applied Science from Yale University.

Dennis Fowler

Area of expertise: 
Biomedical
Titan Medical, NewYork-Presbyterian
Bio 

Dennis Fowler is currently a consultant for medical device companies. He received his M.D. in 1973 from Kanas University and his MPH from Columbia University in 2008. Formerly, he was Executive Vice President for Clinical and Regulatory Affairs at Titan Medical Inc; Gerald and Janet Carrus Professor of Surgical Science at Columbia; Director of the Simulation Center at Columbia; V.P.-Medical Director of Perioperative Services at New York Presbyterian Hospital; and General Surgery Division Chief at Cornell. After many years as an academic surgeon, he now focuses on the clinical and regulatory aspects of commercializing innovative medical technology that will bring value to healthcare.

Ehud Geller

Area of expertise: 
Biomedical
Medica Partners, Ikapharm, Interpharm, Teva Pharmaceuticals Group
Bio 
Dr. Ehud Geller has been active in the health care/biopharma and life science industries for over 30 years. The former president and CEO of Interpharm Laboratories, Ltd., he presided over the growth of this company from the seed stage to the development of Rebif – selling annually ~ $2.5 bil. Prior to that, Dr. Geller was the president of the Pharmaceutical Division of Teva and Executive VP of the Teva Group, the world’s largest generic drug company. At Teva he led the merger of the pharmaceutical business involved in the acquisition of Ikapharm Ltd., and the pioneered strategy of Teva´s entry into the U.S. market. Earlier, Dr. Geller conducted pharmaceutical research at Wyeth Laboratories in the U.S. Dr. Geller has a B.Sc. degree in chemical engineering from Columbia University, an MBA, and Ph.D. degrees in pharma/chemical engineering from Drexel Institute. He serves as founder and director of biotech and device health care companies.

Rana K. Gupta

Area of expertise: 
Biomedical
HistoRx, Navigator Technology Ventures, yet2.com
Year Served: 
Bio 

Rana Gupta has spent the last 12 years investing in and developing novel technologies. His passion for entrepreneurship is concentrated in entrepreneurial finance and technology development. Most recently, Mr. Gupta was CEO of HistoRx, a cancer diagnostics company and Yale University spin-out. He ran HistoRx for six years until selling it to Novartis AG in September 2012. Prior to HistoRx, Mr. Gupta was Managing Director at Navigator Technology Ventures (NTV), an early stage technology venture capital firm spun out of Draper Laboratory and based in Cambridge, MA. Six of NTV’s investments were laboratory or university spin-outs. Prior to his position with NTV, Mr. Gupta was Product Manager for Global Services with yet2.com, a B2B marketplace for technology transfer. Before yet2.com, Mr. Gupta founded IndoSine U.S. Link, Ltd., a business development company that helped clients expand international businesses between India, China, and the U.S. While running IndoSine, Mr Gupta co-founded a wireless software company, International Solutions, for which he served as Vice President of Sales and Marketing. Previous to IndoSine, he served as Manager, PRC Investment Strategy for Zeneca Pharmaceuticals in Beijing, China. At Zeneca, Mr Gupta was responsible for the China manufacturing strategy, for which he secured a $22M investment from the Board of Directors. For the last eight years, Mr Gupta has been teaching in BU’s entrepreneurship program in the areas of entrepreneurial finance and technology development. He holds an MBA in Finance and International Business from New York University's Stern School of Business, an MS in Operations Research from Stanford University, and a BA in Mathematics from Earlham College. More detalied information can be found here.

 

 

Haro Hartounian

Area of expertise: 
Biomedical
DIAVACS, Allied Bioventures, Vyteris, Protagenic Therapeutics, Microislet, Depotech, DuPont
Bio 

Haro Hartounian is a Biotechnology & Pharmaceutical executive with a record of achieving aggressive goals in large pharmaceutical, start-up biotechnology, and medical device companies by positioning capital, people, intellectual property, systems, and internal disciplines for successful long-term growth. Throughout his career, his blend of scientific knowledge and business acumen has allowed Haro to drive multiple products from bench to commercialization.

Haro is currently the Executive Director for Biopharmaceutical iLab at New Jersey Innovation Institute and Adjunct Associate Professor at Columbia' University's Chemical Engineering Department.

He was formerly the CEO and Co-Founder of DIAVACS, a clinical-stage biotechnology company whose mission is to treat auto-immune diseases, until 2014.

In 2011, he founded Allied Bioventures, a business advisory service working with companies in the life sciences industry. Some of his clients have included DSC Med; Hepalife Biosystems, Inc.; and Lipose. Haro also serves as QED Advisor for member companies in the University City Science Center.

From 2008 to 2011, Haro was President and CEO of Vyteris, Inc., where he led the company through a successful turnaround, infrastructure redesign, and reorganization, and renewed the firm’s viability and momentum as a high-potential player in the transdermal drug delivery market.

From 2006 to 2008, Haro was Founder, Director and CEO of Protagenic Therapeutics Inc., a biotechnology company which he founded to develop treatments for neurological disorders.

From 2001 to 2006, Haro was President and COO of Microislet, Inc., where he established Microislet as a major player in the field of cell therapy for treatment of Type 1 diabetes.

Previously, he led process development and engineering teams for Depotech Corporation, and was a Research Engineer at DuPont Central Research and Development.

Haro has held public and private Board memberships at Vyteris, MicroIslet, and Protagenic Therapeutics. He was also a lecturer at the Department of Bioengineering at the University of California, San Diego and Adjunct Assistant Professor at Drexel University.

Barry Kappel

Area of expertise: 
Biomedical
ContraFect Corporation, Sapience Therapeutics
Year Served: 
Bio 

Barry Kappel is biotechnology entrepreneur and executive. He is driven to help develop and foster the biotechnology community in New York, and actively looks for technologies from New York-based academic institution that may potentially be developed into therapeutics. Most recently, Barry was a member of the founding team of ContraFect Corporation, which he joined in 2009 as the second employee. As the Senior Vice President of Business Development at a small biotechnology company, he was involved in all aspects of the company, including financing activities, licensing of the company's key technologies, establishing scientific collaborations with academic and corporate partners, presenting to regulatory authorities, and developing corporate strategy. ContraFect Corporation is now publicly traded (NASDAQ: CFRX) and has its first drug in human clinical trials. Prior to ContraFect, Barry was a Senior Consultant at Easton Associates, LLC, a boutique life science consulting firm located in Manhattan. In this capacity, he performed a wide range of activities, including the commercial assessment of preclinical and clinical compounds for Pharmaceutical and Biotechnology companies. Easton Associates has since been acquired by Navigant Consulting.

Barry received his B.A. in chemistry from Emory University, his Ph.D. in immunology and pharmacology from the Weill Graduate School of Medical Sciences and Memorial Sloan-Kettering Cancer Center, and his MBA from the S.C. Johnson Graduate School of Management at Cornell University.

Sam Kongsamut

Area of expertise: 
Biomedical
Rudder Serendip LLC, Sanofi
Year Served: 
Bio 

Sam has over 20 years of pharmaceutical R&D and business development experience at a succession of five different companies (Hoechst-Roussel Pharmaceuticals Inc, Hoechst Marion Roussel, Aventis, Sanofi-Aventis, now Sanofi), experiencing a company purchase, a merger of equals, a takeover, and a "transformation", all while remaining in Bridgewater, NJ. Sam managed various-sized groups of scientists in biochemical pharmacology that served multiple project teams in the neuroscience area, and was a member of the CNS Board that managed the CNS project portfolio. He led or worked on a variety of multi-disciplinary drug discovery and development projects covering a range of technologies and therapeutic indications in neuroscience and aging (OCD, anxiety-depression, schizophrenia, Alzheimer's Disease, Parkinson's Disease, sleep disorders, multiple sclerosis, spinal cord injury, stroke, hearing loss, pain, circadian rhythm disorders, urology, musculoskeletal disorders), helping to translate animal pharmacology to human pharmacology, including being involved with two marketed drugs that are now helping patients. From 2009-2012, Sam was Director of External Innovation at Sanofi-Aventis, using his experience to identify opportunities for collaboration and licensing for broad therapeutic interests within the Aging Unit. Since leaving Sanofi in 2012, Sam founded Rudder Serendip LLC, a consulting practice that serves clients at universities, foundations and biotechnology companies with advice on R&D plans and business development. Sam obtained a PhD at the University of Chicago and received postdoctoral training at Cornell and Yale Universities. More detailed information can be found here.

 

Jerry Korten

Area of expertise: 
Biomedical
GE, iSonea Medical, Versamed Inc
Year Served: 
Bio 

Jerry is a Medical Device Company Executive with expertise in product development, business development and regulatory approval planning. Previously the CEO of Versamed, Inc. which was sold to GE Healthcare where he served as GM for business development during the transition. He is now working as an advisor to investment bankers in the healthcare field and serves as a mentor to inventors in academia for the NYC Investment Fund. Jerry is a Director for iSonea Medical and has been a Director for three medical device companies. His technical expertise is in algorithm development using digital signal processing and instrumentation design with a focus on cardio-pulmonary measurements and embedded engineering design. More detailed information can be found here

Francis Lee

Area of expertise: 
Biomedical
GLG, McKinsey, Sanofi-Aventis
Year Served: 
Bio 

Francis leads the life-science Strategic Projects team at Gerson Lerhrman Group (GLG). In this role he helps clients generate strategic insights leveraging GLG’s expert network to help top hedge funds and private equity firms as well Fortune 500 corporations. Prior to GLG, Francis trained and specialized in psychiatry in the UK. He began his commercial career at Sanofi-Aventis which was followed by several years McKinsey & Co. He left to explore start-up opportunities and continued consulting for the life-science industry building his own client base and was recently asked to join GLG to help build their new consulting division which has now grown to a team of 8 people in less than one year. He has significant experience in life-cycle management through more than 7 product launches (over half were blockbusters) and evaluation of loss of expiration strategies for several brands; in particular he has a key strength in understanding medical levers to achieve commercial goals. Francis holds a MD and BSc from University of Birmingham, UK and a MBA from Columbia University.

Keith Lenden

Area of expertise: 
Biomedical
Golgi Therapeutics, Abide Therapeutics, Receptos
Year Served: 
Bio 

As the Founder & CEO of Golgi Therapeutics, Keith is building a strategically focused, early stage biopharmaceutical product funding and development business. The Golgi approach stems from Keith’s 20+ years working at the intersection of biotech innovation, entrepreneurship and venture capital.

Keith has co-founded two successful biotech companies – Receptos (S1P biology and GPCR structure based drug discovery, acquired by Celgene in 2015) and Abide Therapeutics (cannabinoid biology and serine hydrolase drug discovery, partnered with Celgene in 2014). Keith has also served as the Head of Corporate Development for both public and private biopharmaceutical companies (Esperion Therapeutics, Maxygen, Acologix and Genteric). Keith started his career in biotechnology at LEK Consulting.

Keith is an active member and has served on the faculty of the Licensing Executives Society, is a Certified Licensing Professional and has worked with multiple committees of the Biotechnology Industry Organization.

Keith earned an MBA from UC Berkeley’s Haas School of Business and was a Price Institute for Entrepreneurial Studies Venture Capital Fellow. Keith also studied engineering at Dartmouth College’s Thayer School. Keith is married with two daughters and enjoys live music, hiking, skiing and woodworking.

As a member of Class 16, Keith served his fellowship at both Maxygen and Abide Therapeutics under the mentorship of James Sulat (Maxygen) and Robert Nelsen (ARCH Venture Partners).

Bob Sheehy

Area of expertise: 
Biomedical
Foundation Medical Partners, Genstar Capital, United Healthcare
Year Served: 
Bio 

Bob currently serves as an Executive Partner for Foundation Medical Partners and as a member of the Strategic Advisory Board for Genstar Capital. He is on the boards of Kips Bay Medical, Netsmart Technologies, Univita Health and Valence Health. He also serves as an advisor for Cognizant Technology Solutions and the University of Michigan School of Public Health. Bob began his career at Peak Health Plan, a small start-up which was acquired by United Healthcare. After progressing through a series of general management roles, he became CEO of United Healthcare in 2000. In this role, he was responsible for the strategy and results of United Health Group’s insurance and health plan operations. Bob retired from United Health Group in 2009. Bob has B.S. and M.H.S.A degrees from the University of Michigan.

 

Natalie Tucker

Area of expertise: 
Biomedical
MELA Sciences
Year Served: 
Bio 

Natalie Tucker specializes in medical device commercialization and business development strategies. As the Director of Business Development for MELA Sciences Imaging Technologies, she is responsible for the strategy and results of software driven imaging products. MELA Sciences, Inc. is a medical device company that focuses on innovative medical technologies for physicians. Natalie emphasizes regulatory and reimbursement policies to drive product design and commercial success. She is a co-inventor of MELA Sciences Optical Spectral 3D Dermal Imaging System and also serves as a consultant to early stage medical device companies.

Natalie entered the field of medical device commercialization through the professional sports industry where she competed globally for eight years. She started and operated her own company where she consulted on business strategy and health management for clients. She worked in over 15 countries and was the feature of national advertising campaigns promoting future leaders.

Today, Natalie enjoys the opportunity to integrate emerging medical technologies with the needs and opportunities available in professional sports. Natalie received her B.S. in Kinesiology from Indiana University.

Lee Wrubel

Area of expertise: 
Biomedical
Egon Zehnder, Flare Capital Partners, Foundation Medical Partners, Highland Capital Partners, Canaan Partners
Year Served: 
Bio 
Lee brings more than two decades of venture capital experience to his role at Foundation Medical Partners and has a passion for healthcare information and medical technology companies. 
 
Prior to co-founding FMP in 2001, Lee served as an investment professional with Highland Capital Partners and Canaan Partners where he worked closely with the management of a large number of private companies. He began his business career as a consultant at The Wilkerson Group, a healthcare-focused management consulting company.
 
Lee currently serves on the Translational Research Advisory Committee of the Muscular Dystrophy Association and is a member of the Commercial Advisory Board of the Global Cardiovascular Innovation Center at the Cleveland Clinic. He is also a founder of the Coalition to Cure Calpain 3, a non-profit research organization founded to fund research into a rare form of muscular dystrophy.
 
Representative investments include CardioMEMS, Inc., Circulite, Inc., EndoGastric Solutions, Inc., IlluminOss, Rise Health, Atricure (NASDAQ: ATRC) and CardioNet (NASDAQ: CNET). 
 
Lee earned an A.B. from Lafayette College, an M.D. and Masters in Public Health from Tufts University, and an M.B.A. from Columbia University. Lee also completed a pediatric internship at Mount Sinai Medical Center in New York.
 

Greg Blonder

Area of expertise: 
Tech, Energy
AT&T, AT&T Ventures, Morgenthaler Ventures
Year Served: 
Bio 

Greg Blonder is an inventor, scientist, entrepreneur and author. He is currently Professor of Design and Product Engineering at Boston University.

Greg was born into a family of small business owners, and has always found a way to combine his natural talent for innovative ideas, with a path to commercial realization. Mr. Blonder joined AT&T in 1982, initially studying superconductivity and the quantum phenomena of semiconductor materials. In 1987 he was promoted to head of the Photonics and Electronics Research Department, and then in 1991 to director of the Materials and Technology Integration Research Laboratory. In 1992 he assumed the additional responsibility as the Chief Technical Advisor for Corporate Strategy and Development, where he was involved in selecting technical and business strategies for AT&T, and reported to the AT&T board and senior management team.

In 1995, recognizing the need to focus Bell Labs research activities closer to consumer markets, he started the Customer Expectations Research Lab. This lab (Article in Fast Company) tried to understand human behavior through a variety of statistical and cognitive techniques- and then relate those needs to future products and services. They also pioneered a quantitative approach to scenario planning, which has been adopted by a number of companies. In 1996, after Bell Labs moved to Lucent, Greg help create the Claude Shannon Labs at AT&T.

Greg's personal research at AT&T in the 90's was divided between pioneering compelling new services and inventing new classes of consumer electronics devices (such as the AT&T Wrist Telephone). Much of this research resulted in practical applications and he holds over 100 patents in the areas of green energy technology, optical disk recording, integrated fiber optic devices, displays, toys, computer systems, software services and improved user interfaces. He invented or co-invented the original concepts behind two-factor authentication and visual passwords.

In January 1998 Greg decided to leave AT&T Labs, and follow some of these ideas through to the marketplace by joining AT&T Ventures. From 2000-2008 he became a partner at Morgenthaler Ventures, just as the internet bubble was deflating. Fortunately, Greg comes from a long family tradition of operating small businesses, and was able to help step-in as CEO or lead many post-bubble companies to reasonable landings.

Greg is also a director or advisor at a number of private companies, and frequently writes about venture capital, green technology and the economy for Business Week. He develops new products for selected clients- in the last five years, tens of millions of these products have shipped with revenues in the hundreds of millions of dollars.

Greg is also the science advisor at AmazingRibs.com, the largest barbecue site on the internet, and helps competitive teams and pitmasters up their game.

Over a twenty five year career he has demonstrated a strong passion to strengthen this country's technological and competitive foundation through entrepreneurship and education. He has lectured at Wharton and Columbia Business Schools, taught at Parsons, and is now Professor of Design and Product Engineering in the Mechanical Engineering Department at Boston University.

Mr. Blonder attended the Massachusetts Institute of Technology, where his undergraduate thesis was on phase transitions in liquid crystals. In 1982 he received his MS and Ph.D. in Physics from Harvard University after explaining the physics behind the normal-superconducting transition and sub-harmonic energy gap in point contact junctions.

James Chou

Area of expertise: 
Tech, Energy
Work Market, Shutterstock, American Greetings Interactive
Year Served: 
Bio 

James Chou is a technology executive with 20+ years of enterprise and start-up experience. He is currently the Chief Technology Officer at Work Market, a modern work market and frictionless exchange between business and workers, headquarters in New York City. Prior to joining Work Market, Chou served as CTO and officer for Shutterstock (NYSE:SSTK), where he was a member of the executive team that successfully grew a 80 person start-up leading to an IPO with over $2B market cap in 2012. Before Shutterstock, Mr. Chou served as Senior Vice President and CTO of American Greetings Interactive, the interactive media division of American Greetings Corporation. He’s also held leadership role at Apple, Inc., JP Morgan, and Accenture. He is a member of the Board of Advisors at Duke University’s Center for Entrepreneurship and Innovation. He holds a B.S. in electrical engineering from University at Buffalo and an MBA from Duke FUQUA.

George Cigale

Area of expertise: 
Tech, Energy
Tutor.com, Teachers College
Year Served: 
Bio 

George Cigale founded Tutor.com in 1998 and served as its CEO until 2013. Under George's leadership, Tutor.com became the leading provider of on-demand instructional solutions for students and professionals, with a proprietary technology platform that connects students and professionals to experts for on-demand and personalized help. Students have turned to Tutor.com over 10 million times and counting. Tutor.com was acquired by IAC/InteractiveCorp (NASD: IACI) in December 2012, and George became its Chairman in 2013. Before founding Tutor.com, George spent 15 years in education, software, and Internet industries, including executive positions at The Share Group, Adizes Institute, and The Princeton Review. George has raised over $35MM is venture capital. Since the acquisition of Tutor.com, George founded Abenaki Ventures, an advisory firm providing strategic services for early stage and growing education and internet companies. George serves as a Trustee on the Board of Columbia University Teachers College, and as a Member of the Advisory Council for Johns Hopkins Medicine, Institute for Basic Biomedical Sciences. George previously served on the Boards of Poets House and SIIA Education Division, and Chaired the National Advisory Council for the Johns Hopkins University School of Education. George received a BA in Political Science from the State University of New York at Binghamton, and currently lives in Pleasantville, New York, with his wife and three children. His blog can be found at http://ceotutor.blogspot.com/ and tweeting @gcigale.

Robert Colao

Area of expertise: 
Tech, Energy
radiusIP, Nokia, IBM
Year Served: 
Bio 

Robert Colao is the founder of radiusIP, Inc. - an Intellectual Property consulting and licensing services company serving a client base which includes Fortune 100 companies and individual inventors. radiusIP provides a broad set of IP services addressing client’s IP needs and issues including patent licensing, licensing program development, patent sales and acquisitions, IP negotiations, patent portfolio analysis/development, technology licensing - as well as other areas relating to effective management and monetization of IP. From 2008 to 2012 as Director of Outbound Patent Licensing at Nokia Inc., Bob led the company’s global outbound patent licensing activities/organization. Upon first joining Nokia in 2008 as Director of Patent Licensing, he also formulated and directed the business development of new opportunities expanding the licensing and monetization of the Nokia patent portfolio beyond the mobile handset space. Additionally, he drove the IP elements of numerous Nokia M&A activities (e.g. joint ventures and divestitures), which included the divestiture of Nokia’s wireless modem business. From 2000 to 2008, Bob was with IBM’s Corporate Intellectual Property Licensing organization and held the position of Director of International Licensing. His responsibilities at IBM included: the licensing of patents, technology and copyrights; IP related M&A (divestiture) activities and negotiations; patent pool participation (DVD-6C); as well as leading and establishing IBM’s patent sales process. Prior to 2000, Bob held management positions at IBM which included: hardware and software development in the area of high performance computing; marketing & business development; and strategy & planning. Bob holds a BS/MS in Electrical Engineering from Union College, as well as an MBA. More detailed information can be found here.

 

Siddhartha (Sid) Dalal

Area of expertise: 
Tech, Energy
RAND Corporation, Xerox, Bell Laboratories
Year Served: 
Bio 

Siddhartha (Sid) previously served as the chief technology officer (CTO) at RAND Corporation and a professor at the Pardee RAND Graduate School. At RAND, he was responsible for creating and coordinating strategies and architecture for new technology research and platforms; and for developing potential paths to commercialization, including product licensing and development. Prior to this, Sid served as senior adviser to the RAND President on technology, launching a major initiative in “big data” research systems. He was also the principal technical architect behind a revolutionary early warning system developed by RAND for identifying toxic chemicals among tens of thousands of other compounds which resulted in a first ever spin-off from RAND. Before joining RAND in 2007, Sid was vice president of research at Xerox, in charge of Xerox's worldwide imaging and software services research. He has also worked at Bell Laboratories and at Bellcore/SAIC/Telcordia Technologies, where he served as Chief Scientist and Executive Director. Sid has coauthored over 100 peer reviewed publications and holds patents related to software and network engineering and testing, machine learning, risk analysis, data/document mining, and statistical and econometrics modeling. He is also currently on the board of a start up, Praedicat Inc. Dalal received his B.S. from the University of Bombay and his M.B.A. and Ph.D. from the University of Rochester. More detailed information can be found here.

 

 

Sean Dalton

Area of expertise: 
Tech, Energy
Highland Capital Partners, GTE
Bio 

Sean has served as a general partner at Highland Capital Partners since 1998.

Sean’s approach is straightforward: match big challenges to entrepreneurs with the hunger, experience, and commitment to go all out toward delivering the best solution. To this end, he uses his broad experience in technology to ask the hard questions—questions that determine whether an innovative idea has what it takes to succeed as a business.

Beyond the hunt for game-changing ideas, one of Sean’s favorite day-to-day activities is the recruitment of great people, something he sees as essential for Highland Capital Partners' continued success and evolution.

Sean focuses on disruptive technologies in the mobile, enterprise and media markets. He represents Highland on the boards of Anova Data, CENX, ClearSky Data, ExaGrid, Infinio, QD Vision, Xometry.

Recognized multiple times by the Forbes Midas List as one of the top venture capitalists in the industry, Sean’s previous board seats include AccessLan Communications (acquired by Advanced Fibre Communications), Altiga Networks (acquired by Cisco), CCTV Wireless (acquired by TerreStar), CHiL Semiconductor (acquired by International Rectifier), Covergence (acquired by Acme Packet), Envoy Networks (acquired by Texas Instruments), Ocular Networks (acquired by Tellabs), Optasite (acquired by SBA Communications), P.A. Semi (acquired by Apple), Starent Networks (IPO and subsequently acquired by Cisco), and Telica (acquired by Alcatel/Lucent).

Previously Sean acted as Venture Associate—focusing on communications and electronic commerce—at Fidelity Capital. Before that, he was a Product Manager for GTE (now Verizon), leading the nation’s first DSL trial for Internet access.

Sean holds an M.B.A. from Harvard Business School, an M.S., Electrical Engineering from University of Pennsylvania and a B.S., Electrical Engineering from University of Delaware.

Shane Eten

Area of expertise: 
Tech, Energy
Feed Resource Recovery
Year Served: 
Bio 

Shane Eten is a successful entrepreneur with a passion for creating and capitalizing on sustainable business opportunities. Shane has a proven track record of developing industry disruptive solutions, closing complex sales with fortune 50 clients and building teams capable of delivering customers long-term value. For the past eight years, Shane has focused his efforts on leveraging proven and efficient technologies (both CleanTech and Web-based) to create a business model capable of redefining the waste industry. Today, this profitable venture—Feed Resource Recovery, Inc—designs, deploys and operates food-waste digestion facilities for some of the largest food retailers in the world. As the majority shareholder and board of directors member, Shane is now directing his knowledge and expertise towards finding the next generation of opportunities within the space where business, technology and the environment converge. These days Shane is an active advisor/mentor to numerous start-ups and is frequently retained by VC and PE firms to consult on various projects. More detailed information can be found here.

 

 

Jana Kovacovska

Area of expertise: 
Tech, Energy
Mustard Seed Impact, McKinsey & Co.
Bio 

Jana spent three years at McKinsey & Company, where she worked across several industries (healthcare, education, consumer goods, telecom) and functions (strategy, operations, organization, marketing & sales) in Europe and Asia.

Her other experiences includes pro-bono work for a start-up fostering women in leadership, an internship at Prada, writing for an IT magazine, and research and teaching roles in academia with a focus on methodology and energy security.

Jana holds degrees in International Relations and Journalism from Masaryk University in the Czech Republic and a Masters degree in Quantitative Methods from Columbia University, where she was a Fulbright Scholar.

David Murphy

Area of expertise: 
Tech, Energy
HP, Mercury Interactive, Asera, Tivoli / IBN, McKinsey, Kleiner Perkins, Blue Coat Systems
Year Served: 
Bio 

David Murphy, CTV’s “Founding XIR”, returns to Columbia after completing a several year stint as Chief Operating Officer at Blue Coat Systems. David brings a diverse entrepreneurial experience and perspective that spans thirty years:

  • President & COO, Blue Coat Systems, acquired by Bain Capital from Thoma Bravo
  • BU GM Laser Jet and Enterprise Software, HP Printer Division
  • EVP Corp Dev and later CFO, Mercury Interactive, acquired by HP
  • President, Tivoli Software, after acquired by IBM
  • McKinsey Partner, technology, growth industry focused
  • MBA - Stanford
  • Schlumberger (field engineering)
  • BSCS/MSEE - U. Louisville/Florida Atlantic U.

Currently David focuses on proprietary and angel investment opportunities. He serves on several venture boards and advisories. He is particularly adept regarding technology translation, execution on product adoption and practical growth planning. David is most often seen at 30,000 feet - flying somewhere out in the marketplace to sell a new customer on enterprise technology. At sea level, David is an avid runner, and always good for a debate or competition.

Chaki Ng

Area of expertise: 
Tech, Energy
Viacom, MTV, VH1 and CMT
Year Served: 
Bio 

Chaki Ng is an innovation executive at Viacom. Currently he leads Viacom NEXT which does R&D in emerging areas including VR+AR, IoT and AI. Previously he was SVP Product for brands like MTV, VH1 and CMT and launched 15 apps (iOS/Android/XBOX) and responsive sites with hundreds of millions of video streams annually and covering properties like MTV News and Video Music Awards shows. He co-founded and sold Interactive Constructs, a 70-people adaptive eLearning platform company that powered innovative web products such as Read180 for top publishers (Scholastic, Harcourt, Pearson) that have combined over a billion student/teacher page views annually. Chaki holds PhD and SM degrees in Computer Science from Harvard, MBA from MIT Sloan and BS in CS from Northeastern. His academic research includes sensor networks, market design and pervasive computing. Some of his projects are at www.chaki.com.

Brian P. Phillips

Area of expertise: 
Tech, Energy
TechnoServe, IBM
Year Served: 
Bio 

Brian is a serial technology entrepreneur who now specializes in helping entrepreneurs create, build, and grow their companies. As an entrepreneur, mentor, advisor, CEO, and board member, Brian has worked across a wide range of industries including B2B and B2C software, life sciences and biotech, government / defense industry, manufacturing, supply chain / distribution, agribusiness, and retail. He has worked in 30+ countries on five continents, with strong knowledge of emerging market economies and international business development. Brian has personally been involved in the early stages of a dozen companies, five of which eventually had an exit (two went public, two were acquired, and one was sold via a management buy out). He has raised over $28 million in venture capital. In addition, he launched a new enterprise software division within IBM and was a consulting manager in the Tech practice at Arthur Young & Company (now Ernst & Young). Most recently Brian served for three years as the Global Entrepreneurship Director for TechnoServe, an international nonprofit organization that specializes in economic development in emerging markets. At TechnoServe, Brian was responsible for providing growth services and developing access to finance for over 60,000 SME entrepreneurs globally. As part of this work, Brian has played a leadership role in promoting women’s economic development and female entrepreneurship in emerging economies. Brian serves on the Aspen Institute’s ANDE women’s entrepreneurship task force, which he co-founded. He is an advisor to the United Nations High Commission for Refugees (UNHCR), and has worked with both the U.S. and a number of international governments. He has partnered with and advised a number of multinational corporations including Goldman Sachs, Coca-Cola, Nike, MasterCard, and Walmart, and works closely with the Clinton Foundation. Brian has a passion for bringing good ideas to fruition, for making productive connections, and for leveraging his experience to help entrepreneurs succeed. More detailed information can be found here

 

Mark Pinney

Area of expertise: 
Tech, Energy
Vimeo, AOL, Magnetic, Tremor Video, Tacoda, Acorda Therapeutics, Ceregene and Embol-X
Year Served: 
Bio 

Mark R. E. Pinney, M.B.A., M.Sc., C.F.A. is a seasoned finance executive and serial entrepreneur with a track record in the formation and development of early-stage Internet-based technology companies. He has experience in strategy development, venture and growth capital fundraising, forecasting, valuation, M&A and IPOs.

He is currently CFO of Magnetic, a leading search retargeting company, having joined from Vimeo, a digital video platform company owned by IAC (InterActiveCorp, “IACI”) where he was CFO. Prior to this, he was CFO of Lot18, a consumer facing e-commerce company, and CFO of Tremor Video, a digital video advertising and technology company that went public in 2013. Earlier, he was CFO and Chief Privacy Officer of Tacoda, an internet advertising network and technology company that was purchased by AOL in 2007. In the transition to AOL, he served as SVP, Business Planning at AOL.

Before Tacoda, he was CFO and Director of Acorda Therapeutics, a biotechnology company that went public in 2006, and also Chairman of CanDo, an Internet company offering product and service solutions to people with disabilities. In 1998, he co-founded and was CEO of LifeWire, a company that merged with CanDo in 2000. In 1995, Mr. Pinney co-founded Real Media, an Internet advertising software and services firm that merged to form 24/7 Real Media in 2001. He also participated in the start-up of Acorda Therapeutics. Previously, he was VP, Private Transactions at Dillon Read & Co. (1988-92) and VP, Corporate Finance for Merrill Lynch Capital Markets (1984-88).

Mr. Pinney received his undergraduate degree in engineering at the University of Exeter, England, his MBA from the University of Chicago Graduate School of Business, and his masters degree in electrical engineering from Columbia University; he is also a Chartered Financial Analyst. He has served as a Trustee to the Christopher and Dana Reeve Foundation and on the Advisory Board of the United Spinal Association. He lives in New York City with his wife and three daughters.

William Reinisch

Area of expertise: 
Tech, Energy
Paladin Capital Group, XIV River, Motorola
Year Served: 
Bio 

William Reinisch is a Venture Partner with Paladin Capital Group, a Venture Capital firm, where he is responsible for sourcing and managing venture investments and runs the firm’s New York office. Reinisch is also currently the CEO and Founder of XIV River Consulting LLC. XIV River Consulting specializes in strategy, venture capital, technology, due diligence and innovation for, among others, high tech startups and companies that are pioneering new markets, and venture capital firms. Reinisch is also an Adjunct Professor at Columbia University, New York University, Fashion Institute of Technology and Stevens Institute of Technology. Reinisch previously served as the Vice President in Motorola’s strategy and technology organization. In this role, he was responsible for positioning Motorola for growth in emerging new market segments in addition to intellectual property, standards and the corporate technology portfolio. He was also part of Motorola Ventures, which is Motorola’s corporate venture capital group. Prior to that, Reinisch was vice president of strategy and new initiatives at Motorola. He joined Motorola in 2004 as a strategic advisor to the Chief Strategy Officer, working to define and develop technology, intellectual property and investment strategies for the corporation. Prior to joining Motorola, Reinisch was Senior Vice President of operations and engineering at Magnolia Broadband, where he led efforts in engineering, operations and radio frequency integrated circuit development until 2004. Before that, he led the global technology organization at Multilink Technology Corporation, a company focused on high-speed component solutions for advanced optical networks. Reinisch has also held various positions at ANADIGICS, Inc., including manager of strategic technology alliances. Prior to 1992, he worked for Analog Devices in the company’s semiconductor division. Experienced in many different aspects of the industry in both technology and operations, Reinisch has authored several publications, presentations, and six U.S. patents. He holds a master of business administration degree from Fordham University and a bachelor’s degree in microelectronic engineering from Rochester Institute of Technology.

Adam Siegel

Area of expertise: 
Tech, Energy
Amazon, Fluid, Google [X], Booz & Company
Year Served: 
Bio 

Adam is a serial entrepreneur who has spent the past 10 years developing and launching new companies focused on the interface of computing, electronics, and healthcare. His passion for entrepreneurship focuses on the "lean startup", a method that centers on early customer engagement and hypothesis-driven product development. He is currently CEO and co-founder of Fluid, a mobile health company focused on urology and infectious disease that participated in the fifth class (v5) of the Rock Health accelerator in San Francisco in 2013. Prior to Fluid, he worked at Google [X], where he directed needs assessments and business development for new projects, including Google Glass and the Smart Contact Lens projects. Before Google, he was a management consultant for Booz & Company in Europe and the US, serving Fortune 500 companies in the life sciences and consumer products industries. From 2002-2009, Adam was a Howard Hughes Medical Institute Fellow in the George Whitesides Group at Harvard University, where he co-authored nine publications and eight patent applications, and designed devices that became the founding technologies for Claros Diagnostics (acquired by Opko in 2011) and Diagnostics-for-All, a social enterprise building medical tools for resource-limited settings. Adam hold a B.S. in Electrical Engineering from the University of Michigan, and a Ph.D. in Engineering and Applied Sciences from Harvard. He was a Fulbright Scholar to Germany from 2001-2002. More detalied information can be found here.

 

 

Laura Smoliar

Area of expertise: 
Tech, Energy
Managing Director, Global Innovation Foundry
Year Served: 
Bio 

Laura has spent nearly two decades in Silicon Valley’s technology sector. She co-founded Global Innovation Foundry, LLC in 2014 to connect innovation, market opportunity, and investors between the U.S. and Asia. Her own startup experience building strategic partnerships and raising funds from Asia inform her approach to solving complex problems across different cultures and economies, harnessing the best assets of large corporations and small companies. Laura is a Columbia College graduate and has coached teams through the Entrepreneurship Coaches Network of Columbia University. She also holds a Ph.D. in physical chemistry from the University of California, Berkeley.

Gordon Stewart

Area of expertise: 
Tech, Energy
Bell-Labs / Alcatel Lucent
Year Served: 
Bio 

Gordon has 20 years of diverse experience in intellectual property licensing, business development, and patent portfolio management, in both corporate and university settings. He has training and expertize in both the physical and life sciences. Prior to entering the business of intellectual property he was a researcher in pediatric genetics at the University of Michigan.

As Director of Global IP Strategy and Portfolio Management at Bell-Labs (Alcatel-Lucent), he managed a global portfolio of over 50,000 patent assets, interacting with attorneys, inventors, technical experts, and business units to ensure the portfolio was aligned to maximize value. He developed and implemented strategies to protect the IP of the company by monitoring the most important technologies and the most relevant geographies. He led teams in evaluating the portfolio to identify patents for use against third parties, both defensively and offensively, and those to be pruned for cost-savings purposes. In this role he also worked with Finance to help secure loans against the portfolio, and with M&A when portfolios were acquired or divested. He negotiated patent swaps, sales, and other ownership transactions with third parties. He worked with the company’s New Ventures Group on the intellectual property aspects of venture spin-offs.

Prior to that role, he managed the Data Processing and Multimedia portfolio segments, supporting deals in excess of $500M with major multinational companies. Gordon has personally negotiated licenses for patents and technology transfers in the areas such as superconductivity, imaging, biological research tools, and telecommunications.

Joining Bell Labs a licensing manager in the New Business Development group, he mined the deep and diverse patent portfolio for monetization opportunities in medical and other non-core areas. Gordon started his career in Technology Transfer at the University of Michigan (UofM) as an Associate Licensing Specialist.

Prior to moving to this business role Gordon was a research scientist in the department of pediatrics at UofM where he was also an associate at the Howard Hughes Medical Institute. His research was focused on the genetics of chromosome 21 and the development of genetic research tools. He has publications pertaining to chromosome 21, Down syndrome, Alzheimer’s disease, Huntington’s disease and murine situs inversus.

Gordon has an MBA from the University of Chicago, a PhD in Medical Genetics from the University of Glasgow, and a BSc in Biological Sciences (Genetics) from the University of Edinburgh. He also received postdoctoral training at Harvard Medical School.

More detailed information can be found here.

Wim Sweldens

Area of expertise: 
Tech, Energy
Alcatel-Lucent, Bell Labs
Year Served: 
Bio 

Wim was most recently the President of Alcatel-Lucent’s Wireless Division, where he led the global development and deployment of LTE 4G technology and oversaw the introduction of the award-winning lightRadio small cell portfolio. Earlier in his role as VP of Network Technology, Wim took the company’s Applications Enablement strategy from paper to practice, allowing service providers to open and leverage their networks for the development of new services and applications. As founder and leader of Alcatel-Lucent Ventures, a strategic new business incubator and investment division inside of Bell Labs, Wim managed the lifecycle - from concept to commercialization - for eight ventures, ranging from enterprise and consumer applications to groundbreaking mobile innovations for operators. Wim also developed several compression algorithms including the one used in the JPEG2000 standard. He authored and co-authored several top cited technical papers, was a member of MIT Technology Review's inaugural class of top young innovators (1999 TR100), and was selected by Global Telecoms Business for its "Power 100 of 2009” list. He is a fellow of the IEEE and member of the Royal Belgian Academy of Sciences. Wim received his PhD in Computer Science from the University of Leuven, Belgium. He lives with his family in New Jersey. You can follow him on twitter @wimsweldens. More detailed information can be found here.

Kristen Morrissey Thiede

Area of expertise: 
Tech, Energy
Starry, Google
Year Served: 
Bio 

Kristen Morrissey Thiede is an entrepreneur, leader and connector. Kristen leads Business Development and Corporate Strategy for Starry. She formally ran Business Development and Content Licensing for Google Fiber.

As a Google veteran of 14 years, Kristen has a history of establishing new businesses at global scale. Kristen has led early stage partnership efforts across Google’s global portfolio including the launch of AdSense for content and distribution efforts globally, and Google.org‘s Crisis response team to Haiti, Chile, and Pakistan. She is a graduate of the University of the South with a BA in Political Science, and lives in New York City.

Kathy Timko

Area of expertise: 
Tech, Energy
Virendia LLC, Canoe Ventures, IDT Telecom
Year Served: 
Bio 

Kathy is the founder and CEO of Virendia, LLC where she provides advisory and consulting services to emerging and mid-stage, technology-focused companies. She holds key management and Advisory Board roles in several NY-based start-ups focused on Social Network Engagement, Personalized Online Career Resources, Crowd-sourced News Reporting, and Social Media Marketing for local businesses. In 2009, Kathy was appointed Chief Operating Officer of Canoe Ventures and became interim CEO in 2011. Canoe Ventures, a joint venture of the six leading cable companies, was formed to provide TV networks, advertising agencies and brand managers access to national advanced advertising products and media analytics. Before joining Canoe, Kathy held several senior management positions at IDT, serving as COO and CTO of IDT Telecom where she oversaw the unit's more than $2B retail and wholesale businesses, Kathy also served as COO of Carrier Services and was appointed to the IDT Telecom Board of Directors in 2001. Prior to IDT, Kathy was the EVP of Development and Operations at Call Sciences, a start-up company focused on Personal Number Services, and worked on communications and software systems at Bellcore, and Bolt, Beranek and Newman (BBN). From 2006 - 2010, Kathy served as an independent director on the board of Motionbox, Inc. She holds a B.S. in Mechanical Engineering from Virginia Tech and an M.S. in Computer Science from Boston University. More detailed information can be found here.

Nicholas Wood

Area of expertise: 
Tech, Energy
Emosyn LLC (Silicon Storage Technology), ATMI, Intel
Year Served: 
Bio 

Nicholas was the CEO and founder of Emosyn LLC, a fabless semiconductor company in the smart card and security markets. In April 2005 Nicholas sold the company to Silicon Storage Technology after growing the business to $60m on an annualized basis with 16 patents issued. Prior to founding Emosyn, he was V.P Marketing for ATMI Inc, a semiconductor materials company. Nicholas also spent 10 years with Intel Corporation in Europe. He has a BSc (Honours) in Electrical and Electronic Engineering from University of Manchester Institute of Science and Technology.

Jennifer Gabler

Area of expertise: 
Tech, Energy, Biomedical
The Refinery, Marlborough Street Partners
Year Served: 
Bio 
Jennifer Gabler is a Columbia MBA, CPA and has functioned as the CFO for multiple startup and venture backed companies. Her expertise is translating business plans of entrepreneurs into financial models that can be used to drive businesses forward operationally and engage financing sources. She could be particularly helpful to those Columbia ventures that have already launched and are looking to monetize their IP in a sustainable business model. She will assist companies with modeling their revenue/gross margin, projecting their P&L and balance sheet and sizing up cash requirements under different assumptions. She can also assist Columbia ventures in locating potential sources of capital. She can assist Columbia ventures in the initial set up of their legal and accounting structure, capitalization table modeling, management reporting, internal controls and management of human resources. Her focus is to assist companies in the management of back office operations, allowing the entrepreneurs to focus on developing their IP and customer facing aspects of their business. Her industry experience spans biotech, digital ventures, software and services, engineering/hardware applications, ad/media and customer facing/retail offerings, among many others.  
 
Jennifer has and AB from Dartmouth College, an MBA from Columbia University and has worked as an independent researcher for Harvard Business School on the topic of “Controls and Governance in Private Companies.” She has been a lecturer at Harvard and Tuck Business Schools.  She is part of a CXO consulting group, Marlborough Street Partners, which helps evaluate, revitalize, operate and monetize venture-funded companies.  Her most recent startup is as Co-Founder of The Refinery which is an accelerator for women owned businesses. She is well networked in the CFO, venture and angel investor communities. Jennifer loves “building it from scratch” and is eager to meet with Columbia entrepreneurs.  More information can be found here.
 

Javier Saade

Area of expertise: 
Tech, Energy, Biomedical
US Small Business Administration, GEM Group, Paradigm Ventures
Year Served: 
Bio 

Javier Saade was appointed by the President to be U.S. Small Business Administration’s Associate Administrator, Office of Investment and Innovation (“OII”). He left his post on October 30, 2015. He led the Small Business Investment Company (SBIC), Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR) and the Growth Accelerator Fund Competition programs. He holds a seat on the U.S. Securities and Exchange Commission’s Committee on Small & Emerging Companies appointed by Chairwoman White. His portfolio included: 1) capitalizing thousands of high-growth small businesses and entrepreneurial ecosystems, 2) investing billions of R&D dollars across a broad swath of America's STEM-driven innovation economy, 3) enhancing capital formation paths where investment gaps are widest, and 4) providing thought leadership on a broad set of economic issues which in turn drove making policy and executing agenda priorities.

Key multiagency collaborations he led or was instrumental to included USPTO’s Fast-Track Intellectual Property, Advanced Manufacturing Investment, JOBS Act Education, Diverse Asset Management, Rural Investing, Social Innovation, Impact Investing, Clean Energy Investing, and STEM Entrepreneurship. He regularly worked with Congress and the White House on policies that directly affect high growth small businesses across the country.

Before joining the Obama administration, Javier was in the private sector and has over 20 years of global principal investing, general management, strategic consulting and entrepreneurial experience. He was Managing Director at The GEM Group an emerging markets focused principal investing firm (PE|VC|HF) and a Principal at Paradigm Ventures, a venture capital firm. He was also an institutional client advisor at Bridgewater Associates, the largest hedge fund in the world with about $160 billion in assets. Javier spent his foundational career years as a strategy consultant at two firms, McKinsey & Company and Booz | Allen | Hamilton and held several operational, line management and engineering roles at life sciences giant Abbott Laboratories.

He enjoys building new companies, and has co-founded and been a top executive of three: a media broadcasting network, Air America Radio, a solar energy services company, Atenergy and a marketing & branding agency, Brand Maestro. Just prior to his public service, Javier advised two investment firms: Pacific Community Ventures, a $100 million double-bottom line and mission-driven impact VC firm in San Francisco and Aspen Grove Capital a $1.3 billion family office in Vail. He holds an MBA from Harvard, an MS in Operations & Technology from Illinois Institute of Technology, and a BS in Industrial Management & Manufacturing Engineering from Purdue University.